top of page
Home
Research
Basilea
About
Services
Contact
Partners
Sign up
Blog
More
Use tab to navigate through the menu items.
All Posts
Search
Andrew Keith
6 days ago
Basilea's future in anti-infectives
Brian White
Feb 7
Another Cresemba Pfizer milestone
Brian White
Jan 11
Basilea - a year of significant achievement
Brian White
Jan 9
CHF20m Astellas milestone
Brian White
Dec 23, 2022
Basilea - Cresemba approved in Japan
Andrew Keith
Nov 9, 2022
Basilea - Sustainable profitability
Brian White
Nov 2, 2022
Basilea - Another oncology programme partnered
Brian White
Oct 24, 2022
Basilea - Positive data at IDweek
Brian White
Sep 20, 2022
Basilea - Still capturing value from oncology
Brian White
Sep 8, 2022
Basilea - Focus on anti-infectives apparent
Brian White
Sep 7, 2022
Basilea - Dilution overhang removed
Brian White
Aug 16, 2022
Basilea - H1 results show continued commercial and strategic progress
Brian White
Jul 26, 2022
Diurnal Group - Trading update ahead of R&D Day
Brian White
Jun 28, 2022
Basilea - Positive Phase 3 results
Brian White
Jun 27, 2022
Basilea - New positioning apparent
Brian White
Jun 17, 2022
Basilea - New territory growth
Andrew Keith
Jun 7, 2022
Basilea - The prospects for anti-infectives
Brian White
Apr 27, 2022
Basilea - Boosting the anti-fungal franchise
Brian White
Apr 25, 2022
Diurnal Group - Efmody set for Swiss launch with EffRx
Brian White
Apr 20, 2022
Diurnal Group - European commercial roll-out continues
1
2
3
4
bottom of page